FCG Investment Co Increases Position in Gilead Sciences, Inc. $GILD

Key Points

• FCG Investment Co increased its stake in Gilead Sciences by 83.0%, purchasing an additional 9,326 shares, bringing its total holdings to 20,566 shares valued at approximately $2.3 million.
• Research firms have shown positive outlooks for Gilead Sciences, with multiple upgrades; Truist Financial raised its price target from $108.00 to $127.00.
• Gilead reported quarterly earnings of $2.01 EPS, surpassing analyst expectations, with a revenue of $7.08 billion, indicating a 1.4% year-over-year increase.

FCG Investment Co grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 83.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,566 shares of the biopharmaceutical company's stock after acquiring an additional 9,326 shares during the period. Gilead Sciences accounts for 1.4% of FCG Investment Co's portfolio, making the stock its 20th largest holding. FCG Investment Co's holdings in Gilead Sciences were worth $2,304,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Gabelli Funds LLC bought a new stake in Gilead Sciences during the 4th quarter worth approximately $387,000. Commerce Bank raised its stake in Gilead Sciences by 1.0% during the 4th quarter. Commerce Bank now owns 73,195 shares of the biopharmaceutical company's stock worth $6,761,000 after acquiring an additional 701 shares during the period. Forum Financial Management LP lifted its holdings in Gilead Sciences by 26.1% during the fourth quarter. Forum Financial Management LP now owns 23,525 shares of the biopharmaceutical company's stock valued at $2,173,000 after purchasing an additional 4,867 shares in the last quarter. Finally, First Trust Advisors LP boosted its position in shares of Gilead Sciences by 1.7% in the fourth quarter. First Trust Advisors LP now owns 2,962,221 shares of the biopharmaceutical company's stock worth $273,620,000 after purchasing an additional 48,442 shares during the period. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock valued at $12,349,790 over the last quarter. 0.27% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday. Finally, Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Gilead Sciences Price Performance

NASDAQ:GILD traded up $0.75 during trading hours on Wednesday, reaching $118.73. The stock had a trading volume of 5,623,636 shares, compared to its average volume of 8,312,371. The stock has a market capitalization of $147.32 billion, a PE ratio of 23.65, a PEG ratio of 0.72 and a beta of 0.33. Gilead Sciences, Inc. has a 52 week low of $74.80 and a 52 week high of $121.83. The company has a 50 day moving average price of $112.14 and a two-hundred day moving average price of $108.71. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.